Indeed, in co-culture with human MSC, treatment of primary AML samples with a neutralizing TGFβ1-antibody resulted in enhanced proliferation of both CD34+CD38− and CD34+CD38+ AML cell populations, and improved sensitivity to cytarabine (146). The gene discussed is CD34; the disease is acute myeloid leukemia.